HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
CORPORATE MEDIA RELEASE
NORGINE AND ITS PARTNER SALIX PRESENT NEW DATA FROM PLENVU® (NER1006) PHASE 3 STUDIES AT DIGESTIVE DISEASE WEEK (DDW) 2018
AMSTERDAM. The Netherlands, 5 June 2018. 2.30 PM BST / 3.30 PM CET. Norgine B.V. today with its partner Salix Pharmaceuticals, Ltd. (“Salix”), announced that they will present new data from phase 3 clinical trials for PLENVU® at Digestive Disease Week (DDW) in Washington, D.C., from June 2-5, 2018.
PLENVU® is a low-volume (1L) polyethylene glycol based bowel preparation indicated for adults.
PLENVU® data presented at DDW on 5 June 2018 from 12:00 to 14:00 EST, include:
PLENVU® is approved in Europe and in the US. In Europe, PLENVU® is available through Norgine and in the US through its partner Salix Pharmaceuticals.
Norgine manufactures PLENVU® globally.
Notes to Editors:
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed and marketed innovative products to improve patients’ lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., is headquartered in Bridgewater, New Jersey.
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
PLENVU is a trademark of the Norgine group of companies.
Media Contact :
Isabelle Jouin, T: +44 (0)1895 826237
Follow us @norgine